NCT00798005View on ClinicalTrials.gov

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Severe Peripheral Artery Occlusive Disease
Interventions
DRUG

XRP0038 (NV1FGF)

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY